These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1161 related items for PubMed ID: 27305904

  • 1. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R.
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C.
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [Abstract] [Full Text] [Related]

  • 4. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Di Perri G, Calcagno A.
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE.
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
    [Abstract] [Full Text] [Related]

  • 7. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [Abstract] [Full Text] [Related]

  • 8. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ.
    Clin Infect Dis; 2017 May 15; 64(10):1350-1359. PubMed ID: 28205671
    [Abstract] [Full Text] [Related]

  • 9. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, Lee CT, Song J, Lee JH.
    Antimicrob Agents Chemother; 2016 Jan 15; 60(1):92-8. PubMed ID: 26459901
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H.
    Antimicrob Agents Chemother; 2015 Jan 15; 59(1):38-45. PubMed ID: 25313213
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A.
    Antimicrob Agents Chemother; 2017 Feb 15; 61(2):. PubMed ID: 27855070
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
    Lei Q, Wang H, Zhao Y, Dang L, Zhu C, Lv X, Wang H, Zhou J.
    Medicine (Baltimore); 2019 Oct 15; 98(41):e17523. PubMed ID: 31593125
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA.
    Drugs; 2002 Oct 15; 62(15):2169-83. PubMed ID: 12381217
    [Abstract] [Full Text] [Related]

  • 19. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY, Kinsara AJ, Osoba AO, Wali S, Samman Y, Memish Z.
    Int J Antimicrob Agents; 2001 May 15; 17(5):415-8. PubMed ID: 11337231
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P.
    Antimicrob Agents Chemother; 2017 Aug 15; 61(8):. PubMed ID: 28607022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.